The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
Authors
Keywords
Checkpoint, Denosumab, Immunotherapy, Osteoprotegerin, RANK, RANKL
Journal
Clinical & Translational Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-17
DOI
10.1007/s12094-018-02023-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
- (2018) A.F. de Groot et al. CANCER TREATMENT REVIEWS
- An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer
- (2018) Alexander Liede et al. CLINICAL THERAPEUTICS
- LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells
- (2018) Zhiying Yue et al. FASEB JOURNAL
- RANKL Signaling Sustains Primary Tumor Growth in Genetically Engineered Mouse Models of Lung Adenocarcinoma
- (2018) Julien Faget et al. Journal of Thoracic Oncology
- RANKL and RANK: From Mammalian Physiology to Cancer Treatment
- (2018) Shuan Rao et al. TRENDS IN CELL BIOLOGY
- Influence of estrogen in non-small cell lung cancer and its clinical implications
- (2018) Vianey Rodriguez-Lara et al. Journal of Thoracic Disease
- RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
- (2018) Elizabeth Ahern et al. OncoImmunology
- An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
- (2018) Alexander Liede et al. OncoImmunology
- Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.
- (2018) Michael Gnant et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.
- (2018) Robert E. Coleman et al. JOURNAL OF CLINICAL ONCOLOGY
- Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma
- (2018) André Steven et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Poster Abstracts
- (2018) EUROPEAN JOURNAL OF CANCER
- RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer
- (2017) Shuan Rao et al. GENES & DEVELOPMENT
- Leucine-rich repeat–containing G protein–coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial–mesenchymal transition
- (2017) Weijia Luo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Denosumab: Current Use in the Treatment of Primary Bone Tumors
- (2017) Olga D. Savvidou et al. ORTHOPEDICS
- Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy
- (2017) Eleni Timotheadou et al. Translational Oncology
- The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy
- (2017) Mekonnen Sisay et al. OncoTargets and Therapy
- Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation
- (2017) Cédric Boudot et al. Oncotarget
- RANKL-induced M1 macrophages are involved in bone formation
- (2017) Rong Huang et al. Bone Research
- Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles
- (2016) Sébastien S. Dufresne et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- RANK-RANKL signalling in cancer
- (2016) N. Renema et al. BIOSCIENCE REPORTS
- Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
- (2016) Joanne Kotsopoulos et al. BREAST CANCER RESEARCH AND TREATMENT
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- RANK as a therapeutic target in cancer
- (2016) Eva González-Suárez et al. FEBS Journal
- Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
- (2016) Mark J. Smyth et al. JOURNAL OF CLINICAL ONCOLOGY
- Toward Repurposing Metformin as a Precision Anti-Cancer Therapy Using Structural Systems Pharmacology
- (2016) Thomas Hart et al. Scientific Reports
- New Insights into the Crossroads between EMT and Stemness in the Context of Cancer
- (2016) Isabel Fabregat et al. Journal of Clinical Medicine
- Repurposing medicinal compounds for blood cancer treatment
- (2015) Bronagh McCabe et al. ANNALS OF HEMATOLOGY
- RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs
- (2015) B Beuselinck et al. BRITISH JOURNAL OF CANCER
- Receptor activating NF-κB ligand (RANKL) is a constitutive intracellular protein in resting human basophils and is strongly induced on their surface by interleukin 3
- (2015) Caroline Poli et al. IMMUNOBIOLOGY
- Receptor Activator of NF-κB Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages
- (2015) Taku Fujimura et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects
- (2015) Pan-Feng Wu et al. TUMOR BIOLOGY
- Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma
- (2015) KLEMENS TRIEB et al. Oncology Letters
- Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
- (2015) Michelle A. Lawson et al. Nature Communications
- Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion
- (2015) Stéphanie A Demoulin et al. OncoImmunology
- Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance
- (2014) Imran S. Khan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- NF- B, an Active Player in Human Cancers
- (2014) Y. Xia et al. Cancer Immunology Research
- Effects of RANKL-Targeted Therapy in Immunity and Cancer
- (2014) Michael L. Cheng et al. Frontiers in Oncology
- GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer
- (2013) Jinhua Wu et al. CARCINOGENESIS
- RANK expression on breast cancer cells promotes skeletal metastasis
- (2013) Michelle L. Blake et al. CLINICAL & EXPERIMENTAL METASTASIS
- Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL
- (2013) N C Walsh et al. GENES AND IMMUNITY
- Immunology and bone
- (2013) L. Danks et al. JOURNAL OF BIOCHEMISTRY
- Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer
- (2013) Xianbo Peng et al. PLoS One
- Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast
- (2013) T. Tanos et al. Science Translational Medicine
- Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis
- (2013) Pasquale Pellegrini et al. STEM CELLS
- Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
- (2013) Roger von Moos et al. Journal of Clinical Medicine
- RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
- (2012) M. Palafox et al. CANCER RESEARCH
- Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
- (2012) Giorgio Vittorio Scagliotti et al. Journal of Thoracic Oncology
- RANKL Expression Specifically Observed in Vivo Promotes Epithelial Mesenchymal Transition and Tumor Progression
- (2011) Tamaki Yamada et al. AMERICAN JOURNAL OF PATHOLOGY
- Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
- (2011) R E Langley et al. BRITISH JOURNAL OF CANCER
- The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells
- (2011) M. Shin et al. CARCINOGENESIS
- Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
- (2011) W. C. Dougall CLINICAL CANCER RESEARCH
- RANKL/RANK—beyond bones
- (2011) Reiko Hanada et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling
- (2011) Wei Tan et al. NATURE
- Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients
- (2011) Daniele Santini et al. PLoS One
- Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
- (2010) David Thomas et al. LANCET ONCOLOGY
- RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
- (2010) Eva Gonzalez-Suarez et al. NATURE
- Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
- (2010) Daniel Schramek et al. NATURE
- RANK-RANKL Signaling Pathway Is Critically Involved in the Function of CD4 + CD25 + Regulatory T Cells in Chronic Colitis
- (2009) Teruji Totsuka et al. JOURNAL OF IMMUNOLOGY
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
- (2009) Etienne Meylan et al. NATURE
- Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells
- (2008) Valerie A Odero-Marah et al. CELL RESEARCH
- The Tumor Necrosis Factor Family Receptors RANK and CD40 Cooperatively Establish the Thymic Medullary Microenvironment and Self-Tolerance
- (2008) Taishin Akiyama et al. IMMUNITY
- RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
- (2008) R. E. Miller et al. MOLECULAR CANCER THERAPEUTICS
- NK cells and cancer immunosurveillance
- (2008) I Waldhauer et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started